Related Experiment Video

Updated: Jun 25, 2026

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Infliximab reduces myeloperoxidase concentration in chronic inflammatory joint diseases

Montserrat Feijóo1, Isaac Túnez, Inmaculada Tasset

  • 1Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Córdoba, Córdoba, Spain. fm2tufii@uco.es

Pharmacology
|February 11, 2009
PubMed
Abstract

Insights

Infliximab treatment normalized myeloperoxidase (MPO) levels in patients with chronic inflammatory joint disease. This indicates MPO concentration is linked to disease activity and oxidative stress.

Area of Science:

  • Rheumatology and Immunology
  • Biochemistry

Background:

  • Chronic inflammatory joint diseases are characterized by elevated oxidative stress.
  • Myeloperoxidase (MPO) is an enzyme implicated in inflammatory processes and oxidative damage.

Purpose of the Study:

  • To investigate the effect of infliximab on myeloperoxidase (MPO) concentration in patients with chronic inflammatory joint disease.
  • To assess the relationship between MPO levels, inflammatory markers, and oxidative stress before and after treatment.

Main Methods:

  • Evaluation of 18 patients with chronic inflammatory joint disease, categorized into active and inactive disease groups.
  • Measurement of erythrocyte sedimentation rate, C-reactive protein, white blood cell counts, MPO concentration, and oxidative stress biomarkers.
  • Comparison of parameters before and after infliximab infusion.

Main Results:

  • Patients with active disease exhibited increased MPO concentrations and oxidative stress biomarkers, alongside decreased antioxidant parameters.
  • Infliximab treatment led to the normalization of both inflammatory markers and MPO concentrations.
  • MPO concentration was found to correlate with inflammatory activity.

Conclusions:

  • Myeloperoxidase concentration is associated with inflammatory activity in chronic joint diseases.
  • MPO plays a significant role in sustaining and triggering oxidative stress in these conditions.
  • Infliximab effectively inhibits MPO concentration, suggesting a therapeutic mechanism in managing oxidative stress.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.